Amarin’s Vascepa Positioned For Broad CV Risk Reduction Claim Following US FDA Panel Nod

PS1911_Big-game-fishing_223578337_1200.jpg
US FDA's external advisors voted 16-0 to expand Vascepa's label.

More from US FDA Performance Tracker

More from Regulatory Trackers